Reducing the immunogenicity of fusion proteins
First Claim
Patent Images
1. A fusion protein with reduced immunogenicity comprising:
- a non-immunoglobulin protein andan immunoglobulin protein fused to said non-immunoglobulin protein via a fusion junction,wherein the amino acid sequence of a junction region surrounding the fusion junction is modified by substitution or deletion of one or more amino acids to remove a non-self T-cell epitope,wherein the junction region comprises an IgG region wherein the LSLS amino acid sequence (amino acids 3-6 of SEQ ID NO;
5) is mutated.
3 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.
182 Citations
7 Claims
-
1. A fusion protein with reduced immunogenicity comprising:
-
a non-immunoglobulin protein and an immunoglobulin protein fused to said non-immunoglobulin protein via a fusion junction, wherein the amino acid sequence of a junction region surrounding the fusion junction is modified by substitution or deletion of one or more amino acids to remove a non-self T-cell epitope, wherein the junction region comprises an IgG region wherein the LSLS amino acid sequence (amino acids 3-6 of SEQ ID NO;
5) is mutated. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
Specification